State of the Art Review: Emerging Therapies: The Use of Insulin Sensitizers in the Treatment of Adolescents with Polycystic Ovary Syndrome (PCOS)
Open accessThe DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
PCOS, a heterogeneous disorder characterized by cystic ovarian morphology, androgen excess, and/or irregular periods, emerges during or shortly after puberty. Peri- and post-pubertal obesity, insulin resistance and consequent hyperinsulinemia are highly prevalent co-morbidities of PCOS and promote an ongoing state of excess androgen. Given the relationship of insulin to androgen excess, reduction of insulin secretion and/or improvement of its action at target tissues offer the possibility of improving the physical stigmata of androgen excess by correction of the reproductive dysfunction and preventing metabolic derangements from becoming entrenched. While lifestyle changes that concentrate on behavioral, dietary and exercise regimens should be considered as first line therapy for weight reduction and normalization of insulin levels in adolescents with PCOS, several therapeutic options are available and in wide use, including oral contraceptives, metformin, thiazolidenediones and spironolactone. Overwhelmingly, the data on the safety and efficacy of these medications derive from the adult PCOS literature. Despite the paucity of randomized control trials to adequately evaluate these modalities in adolescents, their use, particularly that of metformin, has gained popularity in the pediatric endocrine community. In this article, we present an overview of the use of insulin sensitizing medications in PCOS and review both the adult and (where available) adolescent literature, focusing specifically on the use of metformin in both mono- and combination therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Franks, S. (1995) · New England Journal of Medicine · doi:10.1056/nejm199509283331307 · Cited by 2,463
Azziz, R., Carmina, E., Dewailly, D., Diamanti-Kandarakis, E., Escobar-Morreale, H. F., Futterweit, W., Janssen, O. E., Legro, R. S., Norman, R. J., Taylor, A. E., et al. (2009) · Fertility and Sterility · doi:10.1016/j.fertnstert.2008.06.035 · Cited by 2,132 · cited 1×
“Whereas the degree of IR in PCOS is greater than that predicted by BMI alone, nearly half of PCOS women are not obese [129] and the degree of visceral adiposity alone is inadequate to explain differences in insulin sensitivity between PCOS and normal women, suggesting that weight loss by itself may be insufficient to…”
BackgroundAmenorrhea associated with bilateral polycystic ovaries
Stein, I. F., & Leventhal, M. L. (1935) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(15)30642-6 · Cited by 2,121 · cited 1×
“The association between disordered carbohydrate metabolism and excessive androgen action in women was first reported in 1921 [26] as “the diabetes of bearded women (diabète des femmes à barbe)”, preceding Stein and Leventhal’s formal description of PCOS [27].”
BackgroundProfound Peripheral Insulin Resistance, Independent of Obesity, in Polycystic Ovary Syndrome
Dunaif, A., Segal, K. R., Futterweit, W., & Dobrjansky, A. (1989) · Diabetes · doi:10.2337/diab.38.9.1165 · Cited by 1,967
Legro, R. S. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.1.165 · Cited by 1,743 · cited 1×
“5% of these women manifested frank T2DM, prevalence rates 5-7 fold higher than those reported in population-based studies of women aged 20-44 [22].”
ResultPrevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.
Ehrmann, D. A., Barnes, R. B., Rosenfield, R. L., Cavaghan, M. K., & Imperial, J. (1999) · Diabetes Care · doi:10.2337/diacare.22.1.141 · Cited by 1,257 · cited 1×
“In addition, the typically gradual transition from impaired glucose tolerance (IGT) to overt T2DM may be accelerated 5 to 10-fold in women with PCOS [20,21].”
BackgroundMoran, L. J., Misso, M. L., Wild, R. A., & Norman, R. J. (2010) · Human Reproduction Update · doi:10.1093/humupd/dmq001 · Cited by 1,108
Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome
Legro, R. S., Barnhart, H. X., Schlaff, W. D., Carr, B. R., Diamond, M. P., Carson, S. A., Steinkampf, M. P., Coutifaris, C., McGovern, P. G., Cataldo, N. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa063971 · Cited by 1,027
Wild, R. A., Carmina, E., Diamanti-Kandarakis, E., Dokras, A., Escobar-Morreale, H. F., Futterweit, W., Lobo, R., Norman, R. J., Talbott, E., & Dumesic, D. A. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2724 · Cited by 1,010 · cited 1×
“These associated metabolic derangements greatly increase a woman’s lifetime risk to develop T2DM and cardiovascular co-morbidities [23,24].”
BackgroundKiddy, D. S., Hamilton‐Fairley, D., Bush, A., Short, F., Anyaoku, V., Reed, M. J., & Franks, S. (1992) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1992.tb02909.x · Cited by 921
Velazquez, E. M., Mendoza, S., Hamer, T., Sosa, F., & Glueck, C. J. (1994) · Metabolism · doi:10.1016/0026-0495(94)90209-7 · Cited by 865 · cited 1×
“Knowledge of the effects of insulin on free androgen levels has prompted multiple trials of the efficacy of drugs that increase insulin sensitivity or reduce insulin levels, including metformin, in the treatment of PCOS [166-171].”
BackgroundNESTLER, J. E., POWERS, L. P., MATT, D. W., STEINGOLD, K. A., PLYMATE, S. R., RITTMASTER, R. S., CLORE, J. N., & BLACKARD, W. G. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-72-1-83 · Cited by 815
Metformin in polycystic ovary syndrome: systematic review and meta-analysis
Lord, J. M., Flight, I. H. K., & Norman, R. J. (2003) · BMJ · doi:10.1136/bmj.327.7421.951 · Cited by 786 · cited 2×
“Most of these studies targeted adult women with this disorder, often yielding promising results with respect to resumption of menstrual cyclicity (in 50-60%), improved percentage of ovulatory cycles, and fertility [reviewed in [170]].”
BackgroundNestler, J. E., & Jakubowicz, D. J. (1996) · New England Journal of Medicine · doi:10.1056/nejm199608293350902 · Cited by 743
Insulin resistance in nonobese patients with polycystic ovarian disease
CHANG, R. J., NAKAMURA, R. M., JUDD, H. L., & KAPLAN, S. A. (1983) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-57-2-356 · Cited by 704
Prevalence and Predictors of the Metabolic Syndrome in Women with Polycystic Ovary Syndrome
Ehrmann, D. A., Liljenquist, D. R., Kasza, K., Azziz, R., Legro, R. S., & Ghazzi, M. N. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1329 · Cited by 703 · cited 6×
“Mothers [86] and sisters [87] of PCOS probands exhibit menstrual irregularities, androgen excess, aberrant lipoprotein profiles, and MBS, with profound defects in insulin secretory function and sensitivity [88].”
BackgroundInfluentialPLYMATE, S. R., MATEJ, L. A., JONES, R. E., & FRIEDL, K. E. (1988) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-67-3-460 · Cited by 693 · cited 2×
“In both lean and obese women with PCOS, metformin (i) decreases insulin levels in association with decreases in clinical indices of ovarian cytochrome P450c17 activity, and (ii) increases SHBG levels, resulting in decreases in free testosterone [60,61,63,64].”
BackgroundHeritability of polycystic ovary syndrome in a Dutch twin-family study
Vink, J. M., Sadrzadeh, S., Lambalk, C. B., & Boomsma, D. I. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1494 · Cited by 647
Low grade chronic inflammation in women with polycystic ovarian syndrome
Kelly, C. C. J., Lyall, H., Petrie, J. R., Gould, G. W., Connell, J. M. C., & Sattar, N. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.6.7580 · Cited by 640
Pasquali, R., Gambineri, A., Biscotti, D., Vicennati, V., Gagliardi, L., Colitta, D., Fiorini, S., Cognigni, G. E., Filicori, M., & Morselli-Labate, A. M. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.8.6738 · Cited by 635 · cited 1×
“Available data indicate that in adult women with PCOS, the addition of metformin therapy to lifestyle modification appears more effective than lifestyle changes alone in maintaining weight loss and in ameliorating metabolic complications of obesity [134,135].”
BackgroundDeUgarte, C. M., Bartolucci, A. A., & Azziz, R. (2005) · Fertility and Sterility · doi:10.1016/j.fertnstert.2004.11.070 · Cited by 589 · cited 1×
“As many as 60% of women with PCOS have BMI values in the overweight or obese range [2] and 70% demonstrate IR and diabetes beyond that predicted by weight alone [12-14].”
BackgroundFollicle dynamics and anovulation in polycystic ovary syndrome
Franks, S., Stark, J., & Hardy, K. (2008) · Human Reproduction Update · doi:10.1093/humupd/dmn015 · Cited by 581
Nelson, V. L., Legro, R. S., Strauss, J. F., & McAllister, J. M. (1999) · Molecular Endocrinology · doi:10.1210/mend.13.6.0311 · Cited by 556
Azziz, R., Marin, C., Hoq, L., Badamgarav, E., & Song, P. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0628 · Cited by 537 · cited 1×
“Hyperinsulinemia consequent to obesity and IR places women with PCOS at far greater risk to develop type 2 diabetes (T2DM) than healthy controls [15]: 15-36% of all T2DM reported in women, irrespective of age, is found in association with PCOS [14,16-19].”
BackgroundEhrmann, D. A., Schneider, D. J., Sobel, B. E., Cavaghan, M. K., Imperial, J., Rosenfield, R. L., & Polonsky, K. S. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.7.4069 · Cited by 461
Zhang, L. H., Rodriguez, H., Ohno, S., & Miller, W. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.23.10619 · Cited by 455
Ehrmann, D. A., Sturis, J., Byrne, M. M., Karrison, T., Rosenfield, R. L., & Polonsky, K. S. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118064 · Cited by 426 · cited 3×
“A genetic etiology for PCOS has been established on the basis of familial clustering [6,21,43-45], with heritability estimates as high as 0.”
BackgroundPrevalence of polycystic ovary syndrome (PCOS) in first-degree relatives of patients with PCOS
Kahsar-Miller, M. D., Nixon, C., Boots, L. R., Go, R. C., & Azziz, R. (2001) · Fertility and Sterility · doi:10.1016/s0015-0282(00)01662-9 · Cited by 406 · cited 1×
“Kahsar-Miller [84] determined the prevalence of PCOS in first-degree relatives of women with PCOS to be as high as 35% (mothers) and 40% (sisters), 5 times that observed in the general population.”
BackgroundImpact of Obesity on the Risk for Polycystic Ovary Syndrome
Yildiz, B. O., Knochenhauer, E. S., & Azziz, R. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1834 · Cited by 401 · cited 2×
“As many as 60% of women with PCOS have BMI values in the overweight or obese range [2] and 70% demonstrate IR and diabetes beyond that predicted by weight alone [12-14].”
BackgroundScreening for Abnormal Glucose Tolerance in Adolescents with Polycystic Ovary Syndrome
Palmert, M. R., Gordon, C. M., Kartashov, A. I., Legro, R. S., Emans, S. J., & Dunaif, A. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.3.8305 · Cited by 354 · cited 1×
“Surrogate measures based on fasting insulin and glucose correlate poorly with gold standard techniques such as the euglycemic clamp in the assessment of insulin dynamics in adult PCOS [50], 2-hr glucose levels in adolescents with PCOS [51], and FSIGT Geller et al.”
MethodSelf-citationCarmina, E., Bucchieri, S., Esposito, A., Del Puente, A., Mansueto, P., Orio, F., Di Fede, G., & Rini, G. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2725 · Cited by 317 · cited 1×
“Whereas the degree of IR in PCOS is greater than that predicted by BMI alone, nearly half of PCOS women are not obese [129] and the degree of visceral adiposity alone is inadequate to explain differences in insulin sensitivity between PCOS and normal women, suggesting that weight loss by itself may be insufficient to…”
BackgroundVanky, E., Stridsklev, S., Heimstad, R., Romundstad, P., Skogøy, K., Kleggetveit, O., Hjelle, S., von Brandis, P., Eikeland, T., Flo, K., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0853 · Cited by 315 · cited 1×
“However, a recent large randomized study of more than 600 women reported no improvement in fertility (as assessed by live birth rates) with use of extended release metformin in women with PCOS compared with clomiphene [172,173].”
BackgroundEvidence for a primary abnormality of thecal cell steroidogenesis in the polycystic ovary syndrome
Gilling‐Smith, C., Story, H., Rogers, V., & Franks, S. (1997) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1997.2321049.x · Cited by 301 · cited 2×
“A genetic etiology for PCOS has been established on the basis of familial clustering [6,21,43-45], with heritability estimates as high as 0.”
BackgroundThe origins and sequelae of abnormal neuroendocrine function in polycystic ovary syndrome
Blank, S. K., McCartney, C. R., & Marshall, J. C. (2006) · Human Reproduction Update · doi:10.1093/humupd/dml017 · Cited by 301 · cited 1×
“Centrally, androgen excess may reduce hypothalamic feedback inhibition, resulting in increased GnRH pulsatility, particularly during puberty [65-67].”
BackgroundBaillargeon, J.-P., Jakubowicz, D. J., Iuorno, M. J., Jakubowicz, S., & Nestler, J. E. (2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2004.02.127 · Cited by 300
Early metabolic abnormalities in adolescent girls with polycystic ovarian syndrome
Lewy, V. D., Danadian, K., Witchel, S. F., & Arslanian, S. (2001) · The Journal of Pediatrics · doi:10.1067/mpd.2001.109603 · Cited by 298 · cited 1×
“Lewy demonstrated ~ 50% reduction in insulin sensitivity in adolescents with PCOS and concluded that profound metabolic derangements must already exist early in puberty [98].”
BackgroundIdentifying Children at Risk for Polycystic Ovary Syndrome
Rosenfield, R. L. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2012 · Cited by 288 · cited 1×
“Overweight and obese adolescent girls, possessing higher circulating insulin levels than lean counterparts [54,66,108], also exhibit elevated androgens, further predisposing them to PCOS [109,110].”
BackgroundHoeger, K. M., Kochman, L., Wixom, N., Craig, K., Miller, R. K., & Guzick, D. S. (2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2004.02.104 · Cited by 278
Arslanian, S. A., Lewy, V., Danadian, K., & Saad, R. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.4.8398 · Cited by 272 · cited 4×
“However, all studies to date report beneficial effects of metformin in lean as well as obese adolescents with PCOS [55,191,195,213].”
BackgroundInfluentialHuber-Buchholz, M.-M. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.4.1470 · Cited by 269 · cited 1×
“Salmi reported improvement in almost every clinical variable associated with PCOS after weight loss [123], and studies have demonstrated that even modest reductions in weight in the range of 2-7% are successful in improving ovulatory function in at least some adult women with this condition [124-126].”
BackgroundSilfen, M. E., Denburg, M. R., Manibo, A. M., Lobo, R. A., Jaffe, R., Ferin, M., Levine, L. S., & Oberfield, S. E. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030617 · Cited by 269
Sir-Petermann, T., Codner, E., Pérez, V., Echiburú, B., Maliqueo, M., Ladrón de Guevara, A., Preisler, J., Crisosto, N., Sánchez, F., Cassorla, F., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2836 · Cited by 260
Hoeger, K., Davidson, K., Kochman, L., Cherry, T., Kopin, L., & Guzick, D. S. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0461 · Cited by 256
Palomba, S., Giallauria, F., Falbo, A., Russo, T., Oppedisano, R., Tolino, A., Colao, A., Vigorito, C., Zullo, F., & Orio, F. (2008) · Human Reproduction · doi:10.1093/humrep/dem391 · Cited by 235
Gambineri, A., Pelusi, C., Genghini, S., Morselli‐Labate, A. M., Cacciari, M., Pagotto, U., & Pasquali, R. (2004) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.01973.x · Cited by 216 · cited 2×
“The combination of metformin with anti-androgens appears promising based on a handful of recent studies in lean [206] and obese [205] young adult women with PCOS, as well as in lean adolescent girls with hyperinsulinemic hyperandrogenism [174,189,190].”
BackgroundIbáñez, L., Potau, N., Zampolli, M., RiquÉ, S., Saenger, P., & Carrascosa, A. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.7.4084 · Cited by 199 · cited 1×
“[101-105] observed increased insulin levels and glucose intolerance throughout maturation.”
BackgroundCostello, M. F., Shrestha, B., Eden, J., Johnson, N., & Moran, L. J. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005552.pub2 · Cited by 197 · cited 1×
“Conversely, a recent Cochrane review on the treatment options for women with PCOS found insufficient data for the efficacy of OCP in preventing endometrial cancers in this adult population [158].”
MethodVryonidou, A., Papatheodorou, A., Tavridou, A., Terzi, T., Loi, V., Vatalas, I.-A., Batakis, N., Phenekos, C., & Dionyssiou-Asteriou, A. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2363 · Cited by 171
Acién, P., Quereda, F., Matallı́n, P., Villarroya, E., López-Fernández, J. A., Acién, M., Mauri, M., & Alfayate, R. (1999) · Fertility and Sterility · doi:10.1016/s0015-0282(99)00184-3 · Cited by 170 · cited 2×
“Finally, the benefit of combining GnRH analog with OCPs to suppress LH pulsatility and androgen production has been investigated, particularly with respect to moderate-severe hirsutism (see below); little added benefit was observed despite the marked increase in cost over OCPs alone [39,151].”
BackgroundQuality of life in adolescent girls with polycystic ovary syndrome
Trent, M. E., Rich, M., Austin, S. B., & Gordon, C. M. (2002) · Archives of Pediatrics & Adolescent Medicine · doi:10.1001/archpedi.156.6.556 · Cited by 164
Sensitization to Insulin Induces Ovulation in Nonobese Adolescents with Anovulatory Hyperandrogenism
Ibáñez, L., Valls, C., Ferrer, A., Marcos, M. V., Rodriguez-Hierro, F., & de Zegher, F. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.8.7756 · Cited by 162 · cited 2×
“Studies indicate that the degree to which metformin therapy is effective in improving the androgenic and metabolic profile in adolescents with PCOS may be related to (i) dose used, particularly when metformin is used as monotherapy, necessitating higher doses [191,200-202]; (ii) the agent with which metformin is combi…”
BackgroundDiamanti-Kandarakis, E., Kouli, C., Alexandraki, K., & Spina, G. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031205 · Cited by 150
Androgens before and after Weight Loss in Obese Children
Reinehr, T., de Sousa, G., Roth, C. L., & Andler, W. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0438 · Cited by 149 · cited 1×
“Consistent with studies in adults, pediatric studies have demonstrated decreases in adrenal and ovarian androgens with weight loss in both obese pre-pubertal and pubertal girls [131,132], and a 59% reduction in free androgen index with a 122% increase in SHBG levels in obese adolescent girls with PCOS [133].”
ResultTrent, M., Austin, S. B., Rich, M., & Gordon, C. M. (2005) · Ambulatory Pediatrics · doi:10.1367/a04-130r.1 · Cited by 147
Ibanez, L., Potau, N., Zampolli, M., Prat, N., Virdis, R., Vicens-Calvet, E., & Carrascosa, A. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.3.8772605 · Cited by 138 · cited 1×
“[101-105] observed increased insulin levels and glucose intolerance throughout maturation.”
BackgroundMastorakos, G., Koliopoulos, C., & Creatsas, G. (2002) · Fertility and Sterility · doi:10.1016/s0015-0282(02)02993-x · Cited by 137
Randomized Placebo-Controlled Trial of Metformin for Adolescents With Polycystic Ovary Syndrome
Bridger, T., MacDonald, S., Baltzer, F., & Rodd, C. (2006) · Archives of Pediatrics & Adolescent Medicine · doi:10.1001/archpedi.160.3.241 · Cited by 126 · cited 3×
“Similar results from a placebo-controlled study by Bridger appear to confirm beneficial effects of metformin monotherapy, at least in the short term [200].”
BackgroundResultNader, S., & Diamanti-Kandarakis, E. (2007) · Human Reproduction · doi:10.1093/humrep/del407 · Cited by 109 · cited 1×
“Most commonly used OCPs contain both an estrogenic component (typically ethinyl estradiol, in doses ranging from 15 to 50 μg) and a progestin with variable potency and androgenicity [141].”
BackgroundIbáñez, L., Ong, K., Ferrer, A., Amin, R., Dunger, D., & de Zegher, F. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-022002 · Cited by 100 · cited 5×
“The bulk of available data in adolescents derives from studies by Ibanez in relatively lean girls with a history of precocious pubarche, hyperinsulinemic hyperandrogenism, and post-pubertal features consistent with PCOS, studies which remain to be replicated [55,189,192,194-197].”
BackgroundInfluentialAllen, H. F., Mazzoni, C., Heptulla, R. A., Murray, M. A., Miller, N., Koenigs, L., & Reiter, E. O. (2005) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem.2005.18.8.761 · Cited by 90 · cited 1×
“In contrast to these data, Allen found concurrent decreases in both IR (measured by fasted baseline glucose/ insulin ratios and QUICKI derivation) and testosterone levels in 35 obese PCOS girls randomized to either metformin or an OCP for six months [220].”
ResultFux Otta, C., Wior, M., Iraci, G. S., Kaplan, R., Torres, D., Gaido, M. I., & Wyse, E. P. (2010) · Gynecological Endocrinology · doi:10.3109/09513590903215581 · Cited by 85 · cited 1×
“Available data indicate that in adult women with PCOS, the addition of metformin therapy to lifestyle modification appears more effective than lifestyle changes alone in maintaining weight loss and in ameliorating metabolic complications of obesity [134,135].”
BackgroundMehta, R. V., Patel, K. S., Coffler, M. S., Dahan, M. H., Yoo, R. Y., Archer, J. S., Malcom, P. J., & Chang, R. J. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1040 · Cited by 47
Cited by
Goodman, N. F., Cobin, R. H., Futterweit, W., Glueck, J. S., Legro, R. S., & Carmina, E. (2015) · Endocrine Practice · doi:10.4158/ep15748.dsc · Cited by 623
Asemi, Z., & Esmaillzadeh, A. (2015) · Hormone and Metabolic Research · doi:10.1055/s-0034-1376990 · Cited by 134
“Increased understanding of the role of insulin resistance in the pathogenesis of PCOS has led to the development of new strategies, including dietary modifica - tions, in the treatment of PCOS [11].”
The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment
An, Y., Sun, Z., Zhang, Y., Liu, B., Guan, Y., & Lu, M. (2014) · Clinical Endocrinology · doi:10.1111/cen.12294 · Cited by 105
Sleep and cardiometabolic function in obese adolescent girls with polycystic ovary syndrome
Nandalike, K., Agarwal, C., Strauss, T., Coupey, S. M., Isasi, C. R., Sin, S., & Arens, R. (2012) · Sleep Medicine · doi:10.1016/j.sleep.2012.07.002 · Cited by 68
PCOS in Adolescence and Type 2 Diabetes
Carreau, A.-M., & Baillargeon, J.-P. (2015) · Current Diabetes Reports · doi:10.1007/s11892-014-0564-3 · Cited by 40
Metadata
- Authors
- of the Drug and Therapeutics Committee of the Pediatric Endocrine Society, Geller, D. H., Pacaud, D., Gordon, C. M., & Misra, M.
- Venue
- International Journal of Pediatric Endocrinology
- Published
- 2011-08-26
- Volume
- 2011
- Issue
- 1
- Pages
- 9-9
- ISSN
- 1687-9848 (ISSN-L)
- 1687-9856
- OpenAlex
- W2157202918
- Cited by
- 72
- References
- 62
- FWCI
- 7.07
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.